Arthur Franken

Arthur Franken is a General Partner at Gilde Healthcare having joined in 2001 as part of the founding team. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics (acquired by Zambon), Calypso Biotech, Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), Noema Pharma, ProQR Therapeutics (IPO on NASDAQ), SpliceBio and STAT-Dx (acquired by QIAGEN). He has been involved in multiple investments and divestments across all funds including Ablynx (IPO on Euronext, acquired by Sanofi-Aventis), Agendia, Amphista Therapeutics, Axonics (IPO on NASDAQ), Calypso Biotech, Eargo (IPO on NASDAQ), uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ), CVRx (IPO on NASDAQ), FIRE1, Pieris (IPO on NASDAQ) and Proverum.

He represents Gilde on the boards of Calypso, Levicept, Moximed, Noema Pharma and SpliceBio and served as a board member for Breath Therapeutics, FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO.